PURPOSE: Sarcoidosis as a multisystem granulomatous disease impacts the health related quality of life in many different ways. Multiorgan involvement contributes to the severity of the disease and the patients’ health status also the therapy used to suppress the granulomatous inflammation. In this study we examined 88 biopsy positive sarcoidosis patients. The focus was to establish the connection between the bone loss (due to the diseases and the therapy) and the patients‘ health status.
METHODS: In the Institute of Pulmonary Diseases, Clinical Center, Beograd, Serbia, the majority of sarcoidosis patients are women, and in this study we analyzed 88 pts out of that number 67 (76%) female. The mean age of female patients 49,57 yrs, SD 11,18.The CT osteodensitometry for bone density was measured in the Institute for Orthopedic Surgery-Banjica, Beograd, Serbia.Patients were divided upon the value of the T score into 3 groups: Group A: T score from 0 to –1 normal; B group: T score from -1 to -2, 5 ostepenia, and C group: T score -2, 5 and beyond osteoporosis. Patients‘ report on their health status was analyzed using the ECOS-16 questionnaire originally designed for female patients with osteoporosis. The impact of sarcoidosis on the quality of life was measured using the SHQ (Sarcoidosis Health Questionnaire).
RESULTS: 18pts has normal T score. (20%) 72% of our patients have T score from -1 to –2, 5 and 8% has T score lower than –2, 5. The mean ECOS-16 score was 2, 24 in the group B and 2, 51 in the group C.The correlations between the SHQ scores and the ECOS-16 scores are statistically significant in the groups B and C in all the domains. (Pearson correlation).
CONCLUSION: Bone loss is a great problem in patients with sarcoidosis (concerning the disease and the therapy).
CLINICAL IMPLICATIONS: Problems caused by the bone loss have severe negative impact on the quality of life in sarcoidosis patients.
DISCLOSURE: Violeta Vucinic, No Financial Disclosure Information; No Product/Research Disclosure Information